Posted by Michael Wonder on 18 Jul 2024
Diakonos Oncology receives FDA fast track designation for pancreatic cancer dendritic cell vaccine
15 July 2024 - Diakonos Oncology announced today that the US FDA has granted fast track designation for the company’s unique dendritic cell vaccine for pancreatic ductal adenocarcinoma.
The company’s dendritic cell vaccines are made with a patient’s dendritic cells and a sample of their tumour.
